RSC-BMCS/SCI Targeted Protein Degradation 5
Event
RSC-BMCS/SCI Targeted Protein Degradation 5
Dates
Wednesday 21st October, 2026 – Thursday 22nd October, 2026
Place
The Fielder Centre, Hatfield
Important links
Social media hashtag – #ProtDeg26
To submit your Abstract, click here
To register, click here
To Sponsor, click here
To apply for a BMCS Bursary please click here
To apply for a SCI Bursary please click here
Synopsis
One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). The targeted protein degradation (TPD) market in 2025 is estimated to be worth between approximately $0.48 billion and $0.65 billion, Expected to reach anywhere from $3.5 billion to $9.85 billion by 2034 or 2035.
This multidisciplinary meeting aims to present the latest developments in the design, biology, chemistry and ADME in TPD within the general themes of PROTACS (including non-oncology targets), Molecular Glues and non-PROTAC degraders. We aim to highlight the newest in enabling technologies such as computational techniques, Direct to Biology, HT synthesis (click, photochemistry etc) and structural biology methods.
Below is a list of confirmed speakers so far:
Alessio Ciulli, University of Dundee – BMCS Hall of Fame Winner
Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact
Joshua Clark, TRIMTECH Therapeutics
Leveraging the Clustering-Based Activation Mechanism of TRIM21 to Degrade Pathological Protein Aggregates
Mattia Cocco, AstraZeneca
Degrader Antibody Conjugates: the good, the bad and the case studies
Peter Cossar, University of Dundee
Lindsay Evans, ICR
Krista Goodman, Larkspur Bio
Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma
Lyn Jones, Dana-Farber Cancer Institute
Rewriting E3 Ligase Function: The Discovery and Development of Cereblon‑Neofunctionalizing Molecular Glues
Jan Kihlberg, Uppsala University
Understanding and Predicting VHL PROTAC Cell Permeability
Suzanne O’Connor, University of Dundee
Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation
Markus Schade, AstraZeneca
AZD9750 and the new Rule-of-oral-PROTACs
Chris Tame, Ternary Therapeutics
Kristin Riching, Promega
Understanding How Cell Context and Intrinsic Factors Contribute to PROTAC Activity
Who should attend
The meeting aims is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.
Student Bursaries
The RSC-BMCS and SCI are offering a small number of bursaries to attend the meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions or non-profit institutions. Preference will be given to members of the RSC-BMCS or SCI. Bursary applications are also invited from RSC or EFMC members who are of working age, but currently unemployed and from those who may have difficulty in funding their attendance. The deadline for applications is Monday 17th August, 2026.
To apply for a BMCS Bursary please click here
To apply for a SCI Bursary please click here
For more information, please email events@hg3.co.uk
Registration
Early Bird Registration Fees (until 9th September, 2026)
RSC/SCI Member £275
Non-Member £375
RSC/SCI Member (Undergraduate and post-graduate) £175
Student Non-Member (Undergraduate and post-graduate) £185
Standard Registration Fees (from 9th September, 2026)
RSC/SCI Member £360
Non-Member £470
RSC/SCI Member (Undergraduate and post-graduate) £250
Student Non-Member (Undergraduate and post-graduate) £260
Registration is now open, please click here.
Call for Abstracts
Abstract submission is now open, to submit your Abstract, click here
Programme
Wednesday 21st October 2026
| 09.45 | Registration Opens |
| 10.25 | Welcome and Opening Remarks: |
| 10.30 – 12.25 | Session 1: |
| 10.30 – 10.55 | Lindsay Evans, ICR Unhooking the Hook: Optimisation of the Aurora A Targeting PROTAC JB170 to CCT400028, an in vitro Degrader Chemical Probe |
| 10.55 – 11.20 | Izidor Sosič, University of Ljubljana Condition-dependent degradation of TAK1 for the targeted therapy in autoimmune and inflammatory diseases |
| 11.20 – 11.45 | Karine Poullennec, BE Discovery Chemistry, UCB Discovery of non-cytotoxic Heterobifunctional Degraders of CDK12 as potential treatment for Myotonic dystrophy (DM1) |
| 11.45 – 12.25 | Krista Goodman, Larkspur Bio Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma |
| 12.25 – 13.30 | Lunch, exhibition and posters |
| 13.30 – 15.40 | Session 2: |
| 13.30 – 13.55 | Martin Ambler, Amphista Therapeutics Expanding Targeted Glue Applications for Clinical Use by Recruiting Novel E3 Ligases |
| 13.55 – 14.20 | Georgia Isom, University of Oxford Molecular Glue-like Degraders of TEM β-Lactamases by Periplasmic Protease DegP |
| 14.20 – 14.45 | Dom Lukauskis, Ternary Therapeutics A computational platform for the design of any molecular glue |
| 14.45 – 15.25 | Lyn Jones, Dana-Farber Cancer Institute Rewriting E3 Ligase Function: The Discovery and Development of Cereblon Neofunctionalizing Molecular Glues |
| 15:25 – 15:40 | Flash Poster Presentations |
| 15.40 – 16:10 | Refreshments, exhibition and posters |
| 16:10 – 18.30 | Session 3: |
| 16.10 – 16.50 | Jan Kihlberg, Uppsala University Understanding and Predicting VHL PROTAC Cell Permeability |
| 16.50 – 17.15 | Rebekah West, University of Cambridge Non-ATP-Competitive PROTACs Against Aurora A Kinase |
| 17.15– 17.30 | Flash Poster Presentations |
| 17.30 – 18:30 | Poster Presentations and networking drinks |
| 19.00 | Conference dinner |
Thursday 22nd October 2026
| 09.00 | Refreshments, exhibition and posters |
| 09.15 – 11.00 | Session 4: |
| 09.15 – 09.55 | Markus Schade, AstraZeneca AZD9750 and the new Rule-of-oral-PROTACs |
| 09.55 – 10.20 | Suzanne O’Connor, University of Dundee Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation |
| 10.20 – 11.00 | Kristin Riching, Promega Understanding How Cell Context and Intrinsic Factors Contribute to PROTAC Activity |
| 11.00 – 11.30 | Refreshments and exhibition |
| 11.30 – 12.45 | Session 5: |
| 11.30 – 11.55 | Joshua Clark, TRIMTECH Therapeutics Leveraging the Clustering-Based Activation Mechanism of TRIM21 to Degrade Pathological Protein Aggregates |
| 11.55 – 12.20 | Peter Cossar, University of Dundee Hijacking Protein Complexes: Induced Chemical Ubiquitination of 14-3-3 Complexes Enables Targeting of Non-Ligandable Proteins |
| 12.20 – 12.45 | Mattia Cocco, AstraZeneca Degrader Antibody Conjugates: the good, the bad and the case studies |
| 12.45 – 13.45 | Lunch, exhibition and posters |
| 13.45 – 15.40 | Session 6: |
| 13.45 – 14.25 | John Spencer, Sussex Drug Discovery Centre, University of Sussex Novel Linkerology in PROTAC Design |
| 14.25 – 14.50 | Ellie Stammers, Cancer Therapeutics, Institute of Cancer Research D2B platform for rapid PROTAC synthesis and testing |
| 14.50 – 15.35 | Alessio Ciulli, University of Dundee – BMCS Hall of Fame Winner Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact |
| 15.35 | Closing Remarks |
Sponsorship/ Exhibitors Opportunities
Registration is now open, please click here.
Organising Committee
Sean Bew, UEA
A Ganesan, Liverpool John Moore University
Katherine Jones, Charles River (Chair)
Jayshree Mistry
Suzanne O’Connor, University of Dundee
Hannah Woodward (Treasurer)
Exhibitors and Sponsors
